124 related articles for article (PubMed ID: 8416208)
1. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.
Slavin-Chiorini DC; Horan Hand PH; Kashmiri SV; Calvo B; Zaremba S; Schlom J
Int J Cancer; 1993 Jan; 53(1):97-103. PubMed ID: 8416208
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
[TBL] [Abstract][Full Text] [Related]
3. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
[TBL] [Abstract][Full Text] [Related]
4. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
Hand PH; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri SV
Cancer Immunol Immunother; 1992; 35(3):165-74. PubMed ID: 1638552
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).
Hutzell P; Kashmiri S; Colcher D; Primus FJ; Hand PH; Roselli M; Finch M; Yarranton G; Bodmer M; Whittle N
Cancer Res; 1991 Jan; 51(1):181-9. PubMed ID: 1988082
[TBL] [Abstract][Full Text] [Related]
6. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317
[TBL] [Abstract][Full Text] [Related]
7. Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody.
Calvo B; Kashmiri SV; Hutzell P; Hand PH; Slavin-Chiorini DC; Schlom J; Zaremba S
Cancer Biother; 1993; 8(1):95-109. PubMed ID: 7529083
[TBL] [Abstract][Full Text] [Related]
8. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
[TBL] [Abstract][Full Text] [Related]
9. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.
Mueller BM; Reisfeld RA; Gillies SD
Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5702-5. PubMed ID: 2198570
[TBL] [Abstract][Full Text] [Related]
10. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
[TBL] [Abstract][Full Text] [Related]
11. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
[TBL] [Abstract][Full Text] [Related]
12. High-affinity chimeric anti-(colorectal carcinoma) antibody correlated to enhanced tumor targeting in biodistribution and imaging.
Qi Y; Matte G; Wilkinson A; Jim X
J Cancer Res Clin Oncol; 1993; 120(1-2):57-62. PubMed ID: 8270610
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
14. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
16. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
Chinn PC; Morena RA; Santoro DA; Kazules T; Kashmiri SV; Schlom J; Hanna N; Braslawsky G
Cancer Biother Radiopharm; 2006 Apr; 21(2):106-16. PubMed ID: 16706631
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
